Zacks Research Issues Positive Forecast for Glaukos Earnings

Glaukos Co. (NYSE:GKOS) – Research analysts at Zacks Research boosted their Q4 2026 earnings estimates for shares of Glaukos in a report released on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings of $0.06 per share for the quarter, up from their prior estimate of $0.03. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos’ FY2027 earnings at $0.82 EPS.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%.

A number of other equities analysts have also weighed in on the company. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. BTIG Research boosted their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They issued a “buy” rating and a $182.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Finally, Wells Fargo & Company upped their price target on shares of Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $100.36 on Monday. Glaukos has a fifty-two week low of $85.23 and a fifty-two week high of $163.71. The business has a 50-day simple moving average of $138.69 and a two-hundred day simple moving average of $137.25. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market cap of $5.68 billion, a price-to-earnings ratio of -34.97 and a beta of 0.99.

Insider Buying and Selling

In related news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,744 shares of company stock valued at $2,504,131. 6.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter worth approximately $43,000. Asset Planning Inc bought a new position in Glaukos in the 4th quarter worth approximately $90,000. CoreCap Advisors LLC boosted its stake in Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 200 shares during the period. Picton Mahoney Asset Management bought a new position in Glaukos in the 4th quarter worth approximately $125,000. Finally, Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 860 shares during the period. 99.04% of the stock is currently owned by institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.